佐力药业：上半年实现净利润3.74亿元 同比增长26.16%

Group 1 - The core viewpoint of the article highlights Zhaoli Pharmaceutical's strong performance in the first half of 2025, with a revenue of 1,599.45 million yuan, an increase of 11.99% year-on-year, and a net profit of 373.50 million yuan, up 26.16%, marking a new high for the company [1] - The growth in performance is primarily driven by core products, with sales of the Wuling series and Bailing series increasing by 7.23% and 38.51% respectively, and the traditional Chinese medicine formula granules business showing a remarkable growth of 56.60% [1] - The company follows a "one body, two wings" strategy, focusing on the medicinal mushroom sector, with main products including the Wuling series (Wuling capsules, Lingze tablets, Linglianhua granules) and Bailing series (Bailing tablets, Bailing capsules) [1] Group 2 - The company has made significant investments in innovative research and development, completing animal pharmacodynamics studies for improved Wuling capsules and advancing clinical trials for Lingxiang tablets [2] - Zhaoli Pharmaceutical has invested 20 million yuan to acquire a 3.15% stake in Lingyi Biotechnology, gaining distribution rights for the Parkinson's pipeline in mainland China [2] - The company is exploring AI technology applications, collaborating with Zhejiang University to establish a joint research center aimed at developing innovative health products using AI technology [2]